ERBB2 and breast cancer: Although early detection of primary tumors and novel treatment strategies have improved outcomes of patients with breast cancer (BC), an increasingly large number of BC patients live long enough to develop lethal BM: 30–50% of patients with Her2+ BC and 25–45% of triple negative BC develop brain metastasis [1,2,3,4,5].